Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases, and their symptoms in Canada, the United States, and internationally. It owns various proprietary drug delivery platforms, including DuraPeel and MMPE that support the development of patented formulations, which facilitate the delivery of active drugs into or through the skin. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; Flexicaine, an anesthetic formulation of lidocaine and tetracaine for the topical treatment of pain conditions; MiCal 1 that is in Phase II clinical trial for the treatment of moderate to severe plaque psoriasis; and MiCal 2, which is in preclinical stage to treat a dermatological skin condition. Its non-prescription skincare products comprise skincare products for aging, acne, rosacea, pigmentation, dehydration, and sensitivity under the Laboratoire Dr Renaud brand; a line of cosmeceutical products for anti-aging medical procedures under the Pro-Derm brand; and a line of products to target and treat various skincare concerns under the Alyria brand. The company has a collaboration agreement with Tetra Natural Health to develop Tetra's dermatology portfolio using the company's transdermal delivery technologies, multiplexed molecular penetration enhancer and DuraPeel; and a development and licensing agreement with Sundial Growers Inc. to develop cannabis and hemp topicals. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.
Read More
